Skip to main content

Advertisement

SpringerLink
Log in

PEX26 Functions as a Metastasis Suppressor in Colorectal Cancer

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background/Aims

Aberrant Peroxisomal Biogenesis Factor 26 (PEX26) occurs in multiple cell process. However, the role of PEX26 in colorectal cancer (CRC) development remains unknown. We aimed to study PEX26 expression, regulation, and function in CRC cells.

Methods

Using the bioinformatic analysis, real-time quantitative PCR, and immunohistochemistry staining, we detected the expression of PEX26 in CRC and normal tissues. We performed functional experiments in vitro to elucidate the effect of PEX26 on CRC cells. We analyzed the RNA-seq data to reveal the downstream regulating network of PEX26.

Results

PEX26 is significantly down-regulated in CRC and its low expression correlates with the poor overall survival of CRC patients. We further demonstrated that PEX26 over-expression inhibits the ability of CRC cell migration, invasion, and epithelial–mesenchymal transition (EMT), while PEX26 knockdown promotes the malignant phenotypes of migration, invasion, and EMT via activating the Wnt pathway.

Conclusion

Overall, our results showed that the loss of PEX26 contributes to the malignant phenotype of CRC. PEX26 may serve as a novel metastasis repressor for CRC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Xie H, Gong Y, Kuang J et al. Computed-tomography-determined sarcopenia is a useful imaging biomarker for predicting postoperative outcomes in elderly colorectal cancer patients. Cancer Res Treat: Off J Korean Cancer Assoc. 2020;52:957.

    Article  Google Scholar 

  2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin. 2018;68:394–424.

    PubMed  Google Scholar 

  3. Tanaka AJ, Okumoto K, Tamura S et al. A newly identified mutation in the PEX26 gene is associated with a milder form of Zellweger spectrum disorder. Cold Spring Harbor Mol Case Stud. 2019. https://doi.org/10.1101/mcs.a003483.

    Article  Google Scholar 

  4. Okugawa Y, Grady WM, Goel A. Epigenetic alterations in colorectal cancer: emerging biomarkers. Gastroenterology 2015;149:1204-1225.e1212.

    Article  CAS  PubMed  Google Scholar 

  5. He H, Chen E, Lei L et al. Alteration of the tumor suppressor SARDH in sporadic colorectal cancer: a functional and transcriptome profiling-based study. Mo Carcinog. 2019;58:957–966.

    Article  CAS  Google Scholar 

  6. Chen E, Yang F, He H et al. Alteration of tumor suppressor BMP5 in sporadic colorectal cancer: a genomic and transcriptomic profiling based study. Mol Cancer. 2018;17:176.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Chen L, Pan X, Hu X et al. Gene expression differences among different MSI statuses in colorectal cancer. Int J Cancer. 2018;143:1731–1740.

    Article  CAS  PubMed  Google Scholar 

  8. Wanders RJ. Peroxisomes in human health and disease: metabolic pathways, metabolite transport, interplay with other organelles and signal transduction. Sub-Cell Biochem. 2013;69:23–44.

    Article  CAS  Google Scholar 

  9. Wanders RJ. Metabolic functions of peroxisomes in health and disease. Biochimie 2014;98:36–44.

    Article  CAS  PubMed  Google Scholar 

  10. Lodhi IJ, Semenkovich CF. Peroxisomes: a nexus for lipid metabolism and cellular signaling. Cell Metab. 2014;19:380–392.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Fujiki Y. Peroxisome biogenesis and human peroxisome-deficiency disorders. Proc Jpn Acad Ser B, Phys Biol Sci. 2016;92:463–477.

    Article  CAS  PubMed  Google Scholar 

  12. Argyriou C, D’Agostino MD, Braverman N. Peroxisome biogenesis disorders. Transl Sci Rare Dis. 2016;1:111–144.

    PubMed  PubMed Central  Google Scholar 

  13. Santos MJ, Quintanilla RA, Toro A et al. Peroxisomal proliferation protects from beta-amyloid neurodegeneration. J Biol Chem. 2005;280:41057–41068.

    Article  CAS  PubMed  Google Scholar 

  14. Fransen M, Nordgren M, Wang B, Apanasets O. Role of peroxisomes in ROS/RNS-metabolism: implications for human disease. Biochim Biophys Acta. 2012;1822:1363–1373.

    Article  CAS  PubMed  Google Scholar 

  15. Singh I, Singh AK, Contreras MA. Peroxisomal dysfunction in inflammatory childhood white matter disorders: an unexpected contributor to neuropathology. J Child Neurol. 2009;24:1147–1157.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Zhang J, Tripathi DN, Jing J et al. ATM functions at the peroxisome to induce pexophagy in response to ROS. Nat Cell Biol. 2015;17:1259–1269.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Mo S, Dai W, Xiang W et al. Prognostic and predictive value of an autophagy-related signature for early relapse in stages I–III colon cancer. Carcinogenesis 2019;40:861–870.

    Article  CAS  PubMed  Google Scholar 

  18. D’Arcangelo D, Giampietri C, Muscio M, Scatozza F, Facchiano F, Facchiano A. WIPI1, BAG1, and PEX3 autophagy-related genes are relevant melanoma markers. Oxidat Med Cell Longev. 2018;2018:1471682.

    Article  Google Scholar 

  19. Cai M, Sun X, Wang W et al. Disruption of peroxisome function leads to metabolic stress, mTOR inhibition, and lethality in liver cancer cells. Cancer Lett. 2018;421:82–93.

    Article  CAS  PubMed  Google Scholar 

  20. Waterham HR, Ebberink MS. Genetics and molecular basis of human peroxisome biogenesis disorders. Biochim Biophys Acta. 2012;1822:1430–1441.

    Article  CAS  PubMed  Google Scholar 

  21. Chen E, Li Q, Wang H, Yang F, Min L, Yang J. MiR-92a promotes tumorigenesis of colorectal cancer, a transcriptomic and functional based study. Biomed Pharmacother Biomed Pharmacother. 2018;106:1370–1377.

    Article  CAS  PubMed  Google Scholar 

  22. Neuhaus C, Eisenberger T, Decker C et al. Next-generation sequencing reveals the mutational landscape of clinically diagnosed Usher syndrome: copy number variations, phenocopies, a predominant target for translational read-through, and PEX26 mutated in Heimler syndrome. Mol Genet Genomic Med. 2017;5:531–552.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Gao FJ, Hu FY, Xu P et al. Expanding the clinical and genetic spectrum of Heimler syndrome. Orphanet J Rare Dis. 2019;14:290.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Dahabieh MS, Ha Z, Di Pietro E et al. Peroxisomes protect lymphoma cells from HDAC inhibitor-mediated apoptosis. Cell Death Differ. 2017;24:1912–1924.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Wen J, Xiong K, Aili A et al. PEX5, a novel target of microRNA-31-5p, increases radioresistance in hepatocellular carcinoma by activating Wnt/β-catenin signaling and homologous recombination. Theranostics 2020;10:5322–5340.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Nieto MA, Huang RY, Jackson RA, Thiery JP. EMT: 2016. Cell 2016;166:21–45.

    Article  CAS  PubMed  Google Scholar 

  27. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009;139:871–890.

    Article  CAS  PubMed  Google Scholar 

  28. Dongre A, Weinberg RA. New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. Nat Rev Mol Cell Biol. 2019;20:69–84.

    Article  CAS  PubMed  Google Scholar 

  29. Ye X, Tam WL, Shibue T et al. Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature 2015;525:256–260.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Rhim AD, Mirek ET, Aiello NM et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012;148:349–361.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Migita T, Ueda A, Ohishi T et al. Epithelial-mesenchymal transition promotes SOX2 and NANOG expression in bladder cancer. Lab Invest: J Tech Methods Pathol. 2017;97:567.

    Article  CAS  Google Scholar 

  32. Yan X, Yan L, Liu S, Shan Z, Tian Y, Jin Z. N-cadherin, a novel prognostic biomarker, drives malignant progression of colorectal cancer. Mol Med Rep. 2015;12:2999–3006.

    Article  CAS  PubMed  Google Scholar 

  33. Aiello NM, Brabletz T, Kang Y, Nieto MA, Weinberg RA, Stanger BZ. Upholding a role for EMT in pancreatic cancer metastasis. Nature 2017;547:E7-e8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Huang RY, Guilford P, Thiery JP. Early events in cell adhesion and polarity during epithelial-mesenchymal transition. J Cell Sci. 2012;125:4417–4422.

    Article  CAS  PubMed  Google Scholar 

  35. Yilmaz M, Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009;28:15–33.

    Article  PubMed  Google Scholar 

  36. Yeung KT, Yang J. Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol. 2017;11:28–39.

    Article  PubMed  Google Scholar 

  37. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol. 2014;15:178–196.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Santiago L, Daniels G, Wang DW, Deng FM, Lee P. Wnt signaling pathway protein LEF1 in cancer, as a biomarker for prognosis and a target for treatment. Am J Cancer Res. 2017;7:1389–1406.

    CAS  PubMed  PubMed Central  Google Scholar 

  39. Yang SC, Liu Y, Li MY et al. FOXP3 promotes tumor growth and metastasis by activating Wnt/beta-catenin signaling pathway and EMT in non-small cell lung cancer. Mol Cancer. 2017;16:1–12.

    Article  Google Scholar 

  40. Bugter JM, Fenderico N, Maurice MM. Mutations and mechanisms of WNT pathway tumour suppressors in cancer. Nat Rev Cancer. 2020;21:5–21.

    Article  PubMed  Google Scholar 

  41. Garcia de Herreros A, Dunach M. Intracellular signals activated by canonical Wnt ligands independent of GSK3 inhibition and beta-catenin stabilization. Cells-Basel 2019;8:1148.

    Article  Google Scholar 

Download references

Funding

This study was supported by grants from the National Natural Scientific Foundation of China (No. 81974378 and No. 82003115) and Shaanxi Fundamental Science Research Project for Chemistry & Biology (22JHQ084).

Author information

Authors and Affiliations

  1. Key Laboratory of Resource Biology and Biotechnology in Western China, Ministry of Education, School of Life Sciences, Northwest University, Xi’an, China

    Bianbian Yan, Lichao Cao, Liyang Gao, Shangqing Wei, Mengwei Wang, Ye Tian, Jin Yang & Erfei Chen

  2. Institute of Preventive Genomic Medicine, School of Life Sciences, Northwest University, Xi’an, China

    Bianbian Yan, Lichao Cao, Liyang Gao, Shangqing Wei, Mengwei Wang, Ye Tian, Jin Yang & Erfei Chen

Authors
  1. Bianbian Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lichao Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Liyang Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shangqing Wei
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mengwei Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ye Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jin Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Erfei Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

EC and JY designed and drafted the manuscript. BY, LG, SW, MW, YT, and DY performed the experiments. LC helped analyzed the statistics. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Erfei Chen.

Ethics declarations

Conflict of interest

The authors reported no conflicts of interest in this work.

Ethical approval

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of Northwest University.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yan, B., Cao, L., Gao, L. et al. PEX26 Functions as a Metastasis Suppressor in Colorectal Cancer. Dig Dis Sci 69, 112–122 (2024). https://doi.org/10.1007/s10620-023-08168-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-023-08168-w

Keywords

Search

Navigation